These phenotypic differences in progressive vs. resolving autoimmunity - i.e. before vs. after CD19.CAR-T cell therapy - in our patient imply mechanisms that activate NK cells in active autoimmunity. This evidence concerns the gene CD19 and Autoimmunity.